神经科

订阅

MedSci主页 / 所有栏目 / 神经科

FDA批准Vumerity治疗复发性MS

2019-10-31 Allan MedSci原创

FDAVumerity复发性MS
关注

Biogen和Alkermes公司近日报道称，FDA已经批准了Vumerity（富马酸地洛西美酯）用于治疗复发形式的多发性硬化症（MS），包括活动性继发进行性疾病的患者。根据2017年签署的一项协议，Biogen在全球范围内拥有Vumerity口服治疗的独家权利，该公司表示，Vumerity将在不久的将来在美国上市

Biogen和Alkermes公司近日报道称，FDA已经批准了Vumerity（富马酸地洛西美酯）用于治疗复发形式的多发性硬化症（MS），包括活动性继发进行性疾病的患者。根据2017年签署的一项协议，Biogen在全球范围内拥有Vumerity口服治疗的独家权利，该公司表示，Vumerity将在不久的将来在美国上市。Biogen首席医学官Alfred Sandrock解释说，Vumerity（以前称为BIIB098和ALKS 8700）是一种新型富马酸盐，相比于Tecfidera（富马酸二甲酯），Vumerity的疗效更好。

多发性硬化症（Multiple sclerosis，MS）是一种脱髓鞘性神经病变，患者脑或脊髓中的神经细胞表面的绝缘物质（即髓鞘）受到破坏，神经系统的信号转导受损，导致一系列可能发生的症状，影响患者的活动、心智、甚至精神状态。


原始出处：

http://www.firstwordpharma.com/node/1677378#axzz63qZhPxYq

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839737, encodeId=e7e91839e3739, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon May 04 23:39:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909792, encodeId=00841909e928a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 17 14:39:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037817, encodeId=b8cb203e8179b, content=<a href='/topic/show?id=203c42521dc' target=_blank style='color:#2F92EE;'>#复发性MS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42521, encryptionId=203c42521dc, topicName=复发性MS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun May 10 10:39:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083858, encodeId=37f220838585b, content=<a href='/topic/show?id=7976185619f' target=_blank style='color:#2F92EE;'>#Vumerity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18561, encryptionId=7976185619f, topicName=Vumerity)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Feb 29 14:39:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]
    2020-05-04 bugit

    #FDA批准#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1839737, encodeId=e7e91839e3739, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon May 04 23:39:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909792, encodeId=00841909e928a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 17 14:39:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037817, encodeId=b8cb203e8179b, content=<a href='/topic/show?id=203c42521dc' target=_blank style='color:#2F92EE;'>#复发性MS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42521, encryptionId=203c42521dc, topicName=复发性MS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun May 10 10:39:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083858, encodeId=37f220838585b, content=<a href='/topic/show?id=7976185619f' target=_blank style='color:#2F92EE;'>#Vumerity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18561, encryptionId=7976185619f, topicName=Vumerity)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Feb 29 14:39:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]
    2020-05-17 hb2008ye

    #复发性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1839737, encodeId=e7e91839e3739, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon May 04 23:39:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909792, encodeId=00841909e928a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 17 14:39:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037817, encodeId=b8cb203e8179b, content=<a href='/topic/show?id=203c42521dc' target=_blank style='color:#2F92EE;'>#复发性MS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42521, encryptionId=203c42521dc, topicName=复发性MS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun May 10 10:39:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083858, encodeId=37f220838585b, content=<a href='/topic/show?id=7976185619f' target=_blank style='color:#2F92EE;'>#Vumerity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18561, encryptionId=7976185619f, topicName=Vumerity)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Feb 29 14:39:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]
    2020-05-10 仁者大医

    #复发性MS#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1839737, encodeId=e7e91839e3739, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon May 04 23:39:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909792, encodeId=00841909e928a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 17 14:39:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037817, encodeId=b8cb203e8179b, content=<a href='/topic/show?id=203c42521dc' target=_blank style='color:#2F92EE;'>#复发性MS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42521, encryptionId=203c42521dc, topicName=复发性MS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun May 10 10:39:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083858, encodeId=37f220838585b, content=<a href='/topic/show?id=7976185619f' target=_blank style='color:#2F92EE;'>#Vumerity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18561, encryptionId=7976185619f, topicName=Vumerity)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Feb 29 14:39:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]
    2020-02-29 drwjr

    #Vumerity#

    0

相关资讯

FDA创新记录，2019年批准了1171个仿制药

美国食品药品监督管理局（FDA）在一份声明中透露，它在2019财年（FY）批准了1171个仿制药，打破了其在2018财年的971个仿制药的纪录。

BMJ：公共财政支持与新药开发

对过去十年中批准的新药相关专利的审查表明，公共支持在至少四分之一新药的后期开发过程中发挥了重要作用

FDA咨询委员会支持撤回对早产药物Makena的批准

AMAG制药公司近日表示，FDA咨询委员会的9名成员投票决定撤回Makena（己酸羟孕酮）的市场准入，而7名小组成员投票决定将该产品推向市场，并加速审批，并需要进行新的确认试验。

局部用米诺环素Foamix获得FDA批准，治疗数百万中度至重度痤疮患者

以色列Foamix制药公司宣布，美国食品药品监督管理局（FDA）批准了其新型AMZEEQ（米诺环素，占4％）局部用泡沫剂，用于治疗9岁及以上的非结节性中度至重度寻常性痤疮的炎性病变，并且是首个获得FDA批准的局部米诺环素。

**款针对高风险流感并发症药物Xofluza，喜获FDA批准

Genentech的Xofluza（baloxavir marboxil）已获得美国食品和药物管理局（FDA）的补充新药申请（NDA）批准，用于症状出现不超过48小时且严重流感并发症高风险的12岁及以上的急性流感人群。

FDA批准Trikafta用于治疗CFTR基因突变的囊性纤维化患者

美国食品和药物管理局（FDA）已批准Vertex的Trikafta（elexacaftor / tezacaftor / ivacaftor和ivacaftor）用于治疗囊性纤维化（CF）。该公司宣布批准将该药用于治疗12岁及以上，囊性纤维化跨膜电导调节剂（CFTR）基因中至少有一个F508del突变的患者。